CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
Etonogestrel contraceptive implantdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02852265
NCT02852265Phase 4Completed
CompareCT.gov

Nexplanon Use in Women Primarily Choosing a Combined Hormonal Contraceptive: a Proof of Concept Trial

University of California, Davis·interventional·Posted Aug 2, 2016·Updated Dec 28, 2018

In Brief

A Phase 4 clinical trial evaluating Etonogestrel contraceptive implant for Contraception. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Women currently using or starting a combined oral contraceptive will be offered study enrollment. Study subjects will have a Nexplanon placed and followed for 6 months to evaluate if they continue the COC, continue the implant, or both, and to assess adverse events and bleeding patterns.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContraception
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2, 2016
Enrollment StartSep 15, 2016
Primary CompletionJul 26, 2017
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.9 years ago

Interventions

Etonogestrel contraceptive implantdrug

Place nexplanon